Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Eur Urol
    June 2021
  1. HU H
    Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.
    Eur Urol. 2021 Jun 29. pii: S0302-2838(21)01859.
    >> Share

  2. KULKARNI GS
    Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01803.
    >> Share

    May 2021
  3. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    >> Share

  4. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    >> Share

  5. SUNDAR S, Symonds P
    Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00345.
    >> Share

  6. BRYAN RT, Catto JWF, Jefferson KP, Patel P, et al
    Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00313.
    >> Share

    April 2021
  7. DURDIN T, Goh A, Pietzak E
    Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00224.
    >> Share

  8. ROUMIGUIE M, Contreras-Sanz A, Black PC
    Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00234.
    >> Share

    March 2021
  9. NECCHI A, de Jong JJ, Raggi D, Briganti A, et al
    Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00212.
    >> Share

    February 2021
  10. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
    Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00141.
    >> Share

  11. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    >> Share

  12. ABU-SALHA Y, Smith AB
    Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer.
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00143.
    >> Share

  13. GRABBERT M, Seiler R, Gratzke C
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial Boorjian SA, Alemozaffar M, Konety BR, et al Lancet Oncol 2021;22:107-17.
    Eur Urol. 2021 Feb 20. pii: S0302-2838(21)00099.
    >> Share

  14. SIGNORINI C, Maffezzini M
    Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00075.
    >> Share

  15. LINDGREN MS, Jensen JB
    Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00085.
    >> Share

  16. CATTO JWF, Downing A, Mason S, Wright P, et al
    Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Eur Urol. 2021 Feb 10. pii: S0302-2838(21)00073.
    >> Share

  17. SORIA F, Gontero P
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.
    Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00066.
    >> Share

  18. ALFRED WITJES J
    Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit.
    Eur Urol. 2021;79:316.
    >> Share

    January 2021
  19. LI R, Lerner SP, Kamat AM
    The Who, What, When, Where, and Why of Bacillus Calmette-Guerin-unresponsive Bladder Cancer.
    Eur Urol. 2021 Jan 13. pii: S0302-2838(21)00001.
    >> Share

  20. WIJBURG CJ, Michels CTJ, Grutters JPC, Rovers MM, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study.
    Eur Urol. 2021 Jan 11. pii: S0302-2838(20)31009.
    >> Share

  21. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
    >> Share

  22. PERERA-BEL J, Bellmunt J
    Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.
    >> Share

  23. FODE M, Jensen CFS, Ostergren PB
    How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media?
    Eur Urol. 2021;79:60-61.
    >> Share

    December 2020
  24. GIANNARINI G, Valotto C, Ficarra V
    Re: Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-institutional Randomized Trial Comparing Robot Versus Open Radical Cystectomy.
    Eur Urol. 2020 Dec 19. pii: S0302-2838(20)30954.
    >> Share

  25. POLETAJEW S, Krajewski W, Zdrojowy R, Kryst P, et al
    Re: Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Dec 10. pii: S0302-2838(20)30928.
    >> Share

  26. HUSSAIN SA, Porta N, Hall E, Salawu A, et al
    Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30937.
    >> Share

  27. DE VERE WHITE R, Dall'Era M
    Re: Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30932.
    >> Share

  28. MANTICA G, Terrone C, Der Merwe AV
    Bladder Cancer and Associated Risk Factors: The African Panorama.
    Eur Urol. 2020 Dec 3. pii: S0302-2838(20)30942.
    >> Share

    November 2020
  29. PANEBIANCO V, Del Giudice F, Narumi Y, Simone G, et al
    Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imag
    Eur Urol. 2020 Nov 28. pii: S0302-2838(20)30861.
    >> Share

  30. VILA-REYES H, Joel DeCastro G, McKiernan JM
    Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai,
    Eur Urol. 2020 Nov 25. pii: S0302-2838(20)30883.
    >> Share

  31. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    >> Share

  32. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    >> Share

  33. BAKER SC, Mason AS, Southgate J
    Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer?
    Eur Urol. 2020 Nov 14. pii: S0302-2838(20)30866.
    >> Share

  34. MITRA AP, Miest T, Dinney CPN
    Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
    Eur Urol. 2020 Nov 3. pii: S0302-2838(20)30809.
    >> Share

    October 2020
  35. RIAZ IB, Hussain SA
    Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
    Eur Urol. 2020 Oct 1. pii: S0302-2838(20)30710.
    >> Share

  36. SHAH A, Tan WP, Inman BA
    National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
    Eur Urol. 2020;78:531-532.
    >> Share

  37. GRIMBERG DC, Shah A, Inman BA
    En Bloc Resection of Bladder Tumors: Style or Substance?
    Eur Urol. 2020;78:570-571.
    >> Share

    September 2020
  38. LOEB S, Reines K, Abu-Salha Y, French W, et al
    Quality of Bladder Cancer Information on YouTube.
    Eur Urol. 2020 Sep 30. pii: S0302-2838(20)30706.
    >> Share

  39. LIEDBERG F, Eriksson P, Sjodahl G
    Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048.
    Eur Urol. 2020 Sep 28. pii: S0302-2838(20)30708.
    >> Share

  40. MEEKS JJ, Dyrsjkot L, Robertson AG
    Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjodahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http:/
    Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30722.
    >> Share

  41. PACKIAM VT, Bhindi B
    Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
    Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30711.
    >> Share

  42. TEOH JY, Huang J, Ko WY, Lok V, et al
    Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.
    Eur Urol. 2020 Sep 21. pii: S0302-2838(20)30697.
    >> Share

    August 2020
  43. PANER GP, Montironi R
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 29. pii: S0302-2838(20)30631.
    >> Share

  44. PFISTER C, Gravis G, Flechon A, Soulie M, et al
    Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Sec
    Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30641.
    >> Share

  45. NECCHI A, Marandino L, Raggi D, Bandini M, et al
    Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?
    Eur Urol. 2020 Aug 27. pii: S0302-2838(20)30639.
    >> Share

  46. FLIPPOT R, Loriot Y
    The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?
    Eur Urol. 2020 Aug 24. pii: S0302-2838(20)30633.
    >> Share

  47. VILA-REYES H, DeCastro GJ, McKiernan JM
    Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscl
    Eur Urol. 2020 Aug 20. pii: S0302-2838(20)30623.
    >> Share

  48. BALDAUF A, Koch R, Heberling U, Thomas C, et al
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30617.
    >> Share

  49. BECKER REN, Meyer AR, Brant A, Reese AC, et al
    Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30564.
    >> Share

  50. MOSTAFID H
    Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?
    Eur Urol. 2020 Aug 9. pii: S0302-2838(20)30598.
    >> Share

  51. WARD DG, Arnold R, Bryan RT
    Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical Utility.
    Eur Urol. 2020 Aug 6. pii: S0302-2838(20)30569.
    >> Share

  52. MONTORSI F, Bandini M, Necchi A
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;78:e75-e76.
    >> Share

    July 2020
  53. MONTORSI F, Bandini M, Briganti A, Dasgupta P, et al
    Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30464.
    >> Share

  54. LINDGREN MS, Bue P, Azawi N, Blichert-Refsgaard L, et al
    The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30541.
    >> Share

  55. WITJES JA, Ribal MJ, van der Heijden AG
    Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol. In press: Ca
    Eur Urol. 2020 Jul 18. pii: S0302-2838(20)30538.
    >> Share

  56. MARIAPPAN P, Johnston A, Padovani L, Clark E, et al
    Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Jul 17. pii: S0302-2838(20)30511.
    >> Share

  57. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
    Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
    Eur Urol. 2020 Jul 16. pii: S0302-2838(20)30508.
    >> Share

  58. VAN RHIJN BWG, Mertens LS, Mayr R, Bostrom PJ, et al
    FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?(dagger).
    Eur Urol. 2020 Jul 15. pii: S0302-2838(20)30531.
    >> Share

  59. COMPERAT E
    Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30448.
    >> Share

  60. WATERHOUSE JV, Hull JH, Linch M
    Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
    Eur Urol. 2020;78:9-10.
    >> Share

    June 2020
  61. MEEKS JJ, Robertson AG
    Immune Signatures Dominate Molecular Subtyping to Predict Response to Neoadjuvant Immunotherapy.
    Eur Urol. 2020;77:711-712.
    >> Share

    May 2020
  62. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30192.
    >> Share

  63. MARIAPPAN P
    Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30218.
    >> Share

  64. VETTERLEIN MW, Gild P, Fisch M, Rink M, et al
    Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of U
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30314.
    >> Share

  65. BABJUK M
    Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30252.
    >> Share

  66. BABJUK M
    Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?
    Eur Urol. 2020;77:581-582.
    >> Share

  67. MANTICA G, Terrone C
    Re: Eugene Shkolyar, Xiao Jia, Timothy C. Chang, et al. Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol 2019;76:714-8.
    Eur Urol. 2020;77:e133.
    >> Share

    April 2020
  68. WITJES JA, Bruins HM, Cathomas R, Comperat EM, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30230.
    >> Share

  69. WOERL AC, Eckstein M, Geiger J, Wagner DC, et al
    Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30255.
    >> Share

  70. KAMAT AM
    Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30322.
    >> Share

  71. PANEBIANCO V, Del Giudice F, Leonardo C, Sciarra A, et al
    VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30306.
    >> Share

  72. LOUIS L, Thomas S, Yohann L, Morgan R, et al
    Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 24. pii: S0302-2838(20)30302.
    >> Share

  73. SHAH A, Grimberg DC, Inman BA
    From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guerin Trials in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30197.
    >> Share

    March 2020
  74. BAI Y, Yang Y, Tang Y
    Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-0
    Eur Urol. 2020 Mar 18. pii: S0302-2838(20)30149.
    >> Share

  75. NECCHI A, Gallina A, Dyrskjot L, Roupret M, et al
    Converging Roads to Early Bladder Cancer.
    Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141.
    >> Share

  76. MOSTAFID H, Babjuk M, Bochner B, Lerner SP, et al
    Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.
    Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146.
    >> Share

  77. BANDINI M, Necchi A
    Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Mus
    Eur Urol. 2020 Mar 14. pii: S0302-2838(20)30150.
    >> Share

  78. HUDDART R, Hall E, Lewis R, Porta N, et al
    Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherap
    Eur Urol. 2020 Mar 10. pii: S0302-2838(20)30119.
    >> Share

  79. NECCHI A, Raggi D, Gallina A, Ross JS, et al
    Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Mar 9. pii: S0302-2838(20)30138.
    >> Share

  80. LI R, Sundi D, Zhang J, Kim Y, et al
    Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin.
    Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118.
    >> Share

    February 2020
  81. LIU W, Liu X, Li S
    Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol.
    Eur Urol. 2020 Feb 26. pii: S0302-2838(20)30120.
    >> Share

  82. KAMOUN A, de Reynies A, Allory Y, Sjodahl G, et al
    Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.
    Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958.
    >> Share

    January 2020
  83. DEL GIUDICE F, Catto JWF, Panebianco V
    Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI
    Eur Urol. 2020 Jan 28. pii: S0302-2838(20)30056.
    >> Share

  84. FRAGKOULIS C, Papadopoulos G, Ntoumas K
    Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patient
    Eur Urol. 2020 Jan 21. pii: S0302-2838(20)30053.
    >> Share

  85. BRIGANTI A, Gandaglia G, Scuderi S, Gallina A, et al
    Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Eur Urol. 2020 Jan 3. pii: S0302-2838(19)30963.
    >> Share

  86. MCGRATH JS, Smith AB, Williams SB
    The Complexity of Complications: How Do We Estimate Morbidity and Target Improvements Following Radical Cystectomy?
    Eur Urol. 2020;77:66-67.
    >> Share

  87. VETTERLEIN MW, Rink M
    Reply to Liang Sun and Yi Feng's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Sta
    Eur Urol. 2020;77:e12-e13.
    >> Share

  88. SUN L, Feng Y
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;77:e10-e11.
    >> Share

  89. KHAN MS, Omar K, Ahmed K, Gan C, et al
    Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2020;77:110-118.
    >> Share

  90. MOSCHINI M, Shariat SF, Black P, Kamat AM, et al
    Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.
    Eur Urol. 2020;77:1-2.
    >> Share

  91. VETTERLEIN MW, Klemm J, Gild P, Bradtke M, et al
    Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index.
    Eur Urol. 2020;77:55-65.
    >> Share

    December 2019
  92. NECCHI A, Bandini M, Calareso G, Raggi D, et al
    Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Eur Urol. 2019 Dec 24. pii: S0302-2838(19)30960.
    >> Share

  93. HUDDART RA, Hall E, Lewis R, Porta N, et al
    Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30840.
    >> Share

  94. THIBAULT C, Lavaud P, Loriot Y
    Studying Rarity in Bladder Cancer.
    Eur Urol. 2019 Dec 4. pii: S0302-2838(19)30891.
    >> Share

    November 2019
  95. WILLIAMS SB, Black PC, Dyrskjot L, Seiler R, et al
    Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Ne
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874.
    >> Share

  96. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees.
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30763.
    >> Share

  97. DEL GIUDICE F, Barchetti G, De Berardinis E, Pecoraro M, et al
    Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Eur Urol. 2019 Nov 4. pii: S0302-2838(19)30757.
    >> Share

    October 2019
  98. YATAI KB, Tran H, Dunning MJ, Wang D, et al
    Sources of Bias Within Consensus Subtypes of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Oct 23. pii: S0302-2838(19)30760.
    >> Share

    September 2019
  99. KETTUNEN K, Bostrom P, Taimen P
    Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://do
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731.
    >> Share

  100. LIU X
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patie
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30734.
    >> Share

  101. KRIEGMAIR MC, Rother J, Grychtol B, Theuring M, et al
    Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674.
    >> Share

  102. KAMOUN A, Reynies A, Allory Y, Sjodahl G, et al
    A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30695.
    >> Share

  103. LEOW JJ, Catto JWF, Efstathiou JA, Gore JL, et al
    Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30690.
    >> Share

  104. SHI MJ, Meng XY, Chen CL, Dyrskjot L, et al
    Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Can
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656.
    >> Share

    August 2019
  105. VARMA M, Delahunt B, Kwast TV
    Reply to Eva Comperat, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. htt
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30676.
    >> Share

  106. YANG A, Cannataro VL, Townsend JP
    Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30662.
    >> Share

  107. BABJUK M, Burger M, Comperat EM, Gontero P, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30660.
    >> Share

  108. LU M, Zhang Y, Xiao Y
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016.
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30605.
    >> Share

  109. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    >> Share

    July 2019
  110. ELANDER NO, Hussain SA
    Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30593.
    >> Share

  111. VOSKUILEN CS, van der Heijden MS, van Rhijn BWG
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30543.
    >> Share

  112. COMPERAT E, Amin M, Reuter V
    Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of Wor
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30541.
    >> Share

  113. PEDERZOLI F, Bandini M, Briganti A, Plimack ER, et al
    Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
    Eur Urol. 2019 Jul 11. pii: S0302-2838(19)30522.
    >> Share

    June 2019
  114. KETTUNEN K, Bostrom PJ, Lamminen T, Heinosalo T, et al
    Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30501.
    >> Share

    May 2019
  115. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    >> Share

  116. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    >> Share

  117. CAO L, Yang Z, Wang B
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30364.
    >> Share

  118. VARMA M, Delahunt B, van der Kwast T
    Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30362.
    >> Share

  119. GSCHWEND JE, Heck M
    Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy:
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30346.
    >> Share

  120. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30344.
    >> Share

  121. DIJKSTRA S, Wijburg CJ
    Re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71: Can the Pattern of Cancer Recurrence T
    Eur Urol. 2019;75:e137.
    >> Share

  122. BOCHNER BH, Dalbagni G
    Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outc
    Eur Urol. 2019;75:e138-e139.
    >> Share

  123. YANG Y, Wei X, Han P
    Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.027.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30343.
    >> Share

  124. TAGUCHI S, Nakagawa T, Fukuhara H
    Re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30345.
    >> Share

  125. SUNDAHL N, Vandekerkhove G, Decaestecker K, Meireson A, et al
    Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2019;75:707-711.
    >> Share

    April 2019
  126. SORIA F, Gontero P
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30275.
    >> Share

  127. SAITA A, Lughezzani G, Buffi NM, Hurle R, et al
    Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging.
    Eur Urol. 2019 Apr 10. pii: S0302-2838(19)30277.
    >> Share

  128. SHI MJ, Meng XY, Lamy P, Banday AR, et al
    APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30261.
    >> Share

  129. GUST KM, Shariat SF
    Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study.
    Eur Urol. 2019;75:695-696.
    >> Share

  130. LERNER SP, Svatek RS
    What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?
    Eur Urol. 2019;75:612-614.
    >> Share

  131. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    >> Share

  132. ABUFARAJ M, Foerster B, Schernhammer E, Moschini M, et al
    Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
    Eur Urol. 2019;75:649-658.
    >> Share

  133. KELLY JD, Tan WS, Porta N, Mostafid H, et al
    BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
    Eur Urol. 2019;75:593-601.
    >> Share

    March 2019
  134. UENO Y, Takeuchi M, Tamada T, Sofue K, et al
    Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Eur Urol. 2019 Mar 25. pii: S0302-2838(19)30198.
    >> Share

  135. MOUW KW, Miyamoto DT, Efstathiou JA
    Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed M
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30195.
    >> Share

  136. CAMPI R, Roupret M
    Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort Study.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30187.
    >> Share

  137. GAKIS G
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30181.
    >> Share

  138. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30174.
    >> Share

  139. NARAYAN VM, Lim AH, Dinney CPN
    Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30165.
    >> Share

  140. RIJNDERS M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, et al
    PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Eur Urol. 2019;75:538-540.
    >> Share

  141. VAN DIJK N, Funt SA, Blank CU, Powles T, et al
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    Eur Urol. 2019;75:435-444.
    >> Share

    February 2019
  142. WITJES JA
    Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30163.
    >> Share

  143. PICHLER R, Heidegger I
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.055.
    Eur Urol. 2019 Feb 22. pii: S0302-2838(19)30159.
    >> Share

  144. GOLDSTEIN MR, Mascitelli L
    Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008.
    Eur Urol. 2019 Feb 11. pii: S0302-2838(19)30093.
    >> Share

  145. CHOUDHURY A, Hoskin PJ
    Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30086.
    >> Share

  146. MONTORSI F, Gandaglia G
    Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641-2.
    Eur Urol. 2019;75:e31.
    >> Share

  147. FICARRA V, Giannarini G, Crestani A, Palumbo V, et al
    Retrosigmoid Versus Traditional Ileal Conduit for Urinary Diversion After Radical Cystectomy.
    Eur Urol. 2019;75:294-299.
    >> Share

    January 2019
  148. EFSTATHIOU JA, Mouw KW, Gibb EA, Liu Y, et al
    Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30012.
    >> Share

  149. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30075.
    >> Share

  150. RADZISZEWSKI P, Poletajew S
    Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-G
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30074.
    >> Share

  151. ZUIVERLOON TCM, Theodorescu D
    Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2019 Jan 17. pii: S0302-2838(18)31024.
    >> Share

  152. LI R, Tabayoyong WB, Guo CC, Gonzalez GMN, et al
    Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.
    Eur Urol. 2019;75:8-10.
    >> Share

    December 2018
  153. VALENBERG FJPV, Hiar AM, Wallace E, Bridge JA, et al
    Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30959.
    >> Share

  154. TAN TZ, Rouanne M, Huang RY, Thiery JP, et al
    Reply to Pontus Eriksson and Gottfrid Sjodahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 T
    Eur Urol. 2018 Dec 5. pii: S0302-2838(18)30952.
    >> Share

  155. ERIKSSON P, Sjodahl G
    Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.08.0
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30953.
    >> Share

  156. VOGELZANG NJ
    Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?
    Eur Urol. 2018;74:754-755.
    >> Share

    November 2018
  157. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    >> Share

  158. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    >> Share

  159. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    >> Share

  160. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    >> Share

  161. PANEBIANCO V, Barentsz J, Narumi Y, Catto JWF, et al
    Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imagi
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30720.
    >> Share

  162. HENRIQUE R, Nunes SP, Jeronimo C
    MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.
    Eur Urol. 2018 Nov 20. pii: S0302-2838(18)30871.
    >> Share

  163. GOODSPEED A, Jean A, Costello JC
    A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Eur Urol. 2018 Nov 7. pii: S0302-2838(18)30835.
    >> Share

  164. COLOMBO R, Rocchini L, Suardi N, Benigni F, et al
    Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30662.
    >> Share

  165. NECCHI A, Messina A, Briganti A
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria With
    Eur Urol. 2018;74:e107-e108.
    >> Share

    October 2018
  166. BABJUK M
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30827.
    >> Share

  167. CHOI W, McConkey DJ
    ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.
    Eur Urol. 2018 Oct 23. pii: S0302-2838(18)30732.
    >> Share

  168. GSCHWEND JE, Heck MM, Lehmann J, Rubben H, et al
    Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737.
    >> Share

  169. GORE JL, Wright JL
    Can We Prevent Bladder Cancer Recurrences?
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30749.
    >> Share

  170. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    >> Share

  171. WITJES JA
    Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30727.
    >> Share

  172. GRIFFIN JL
    Devil in the Detail: Intratumour Heterogeneity and Personalised Medicine for Bladder Cancer.
    Eur Urol. 2018 Oct 3. pii: S0302-2838(18)30724.
    >> Share

  173. PIETZAK EJ, Zabor EC, Bagrodia A, Armenia J, et al
    Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2018 Oct 2. pii: S0302-2838(18)30652.
    >> Share

  174. YUH B, Chan K, Wilson T
    Robotic Cystectomy-Moving from Innovation to Measurable Impact.
    Eur Urol. 2018;74:472-473.
    >> Share

    September 2018
  175. TAN WS, Panchal A, Buckley L, Devall AJ, et al
    Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gueri
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30655.
    >> Share

  176. ARENDS TJH, Witjes JA
    Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bac
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30647.
    >> Share

  177. ABEYSIRI S, Richards T
    Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36:
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30664.
    >> Share

  178. CUMBERBATCH MGK, Jubber I, Black PC, Esperto F, et al
    Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30651.
    >> Share

  179. WARRICK JI, Sjodahl G, Kaag M, Raman JD, et al
    Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30653.
    >> Share

  180. TEOH JYC, Herrmann TRW, Babjuk M
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30657.
    >> Share

  181. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30663.
    >> Share

  182. GARG H, Nayak B, Singh P
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30648.
    >> Share

  183. DYRSKJOT L
    Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30656.
    >> Share

  184. TAN TZ, Rouanne M, Tan KT, Huang RY, et al
    Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619.
    >> Share

  185. GIANNARINI G, Crestani A, Ficarra V
    Re: Stenting Prior to Cystectomy Is an Independent Risk Factor for Upper Urinary Tract Recurrence.
    Eur Urol. 2018;74:395-396.
    >> Share

    August 2018
  186. MOSTAFID H, Palou J, Burger M, Babjuk M, et al
    T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30601.
    >> Share

  187. LINARES-ESPINOS E, Sanchez-Salas R
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 22. pii: S0302-2838(18)30562.
    >> Share

  188. GIANNARINI G, Crestani A, Ficarra V
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 20. pii: S0302-2838(18)30564.
    >> Share

    July 2018
  189. HOVELSON DH, Udager AM, McDaniel AS, Grivas P, et al
    Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Eur Urol. 2018 Jul 19. pii: S0302-2838(18)30475.
    >> Share

  190. PANEBIANCO V, Barentsz J, Narumi Y, Catto J, et al
    Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30457.
    >> Share

  191. KRANTZ D, Hartana CA, Winerdal ME, Johansson M, et al
    Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Eur Urol. 2018 Jul 16. pii: S0302-2838(18)30476.
    >> Share

  192. ECKSTEIN M, Sikic D, Strissel PL, Erlmeier F, et al
    Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30456.
    >> Share

  193. SONPAVDE G, Dranitsaris G, Necchi A
    Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Eur Urol. 2018;74:63-65.
    >> Share

    June 2018
  194. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    >> Share

    May 2018
  195. PANEBIANCO V, Narumi Y, Altun E, Bochner BH, et al
    Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
    Eur Urol. 2018 May 10. pii: S0302-2838(18)30335.
    >> Share

  196. GEYNISMAN DM, Abbosh PH, Plimack ER, Zibelman M, et al
    Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2018;73:760-762.
    >> Share

  197. PEEKER R
    Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification.
    Eur Urol. 2018;73:809-810.
    >> Share

  198. KAMAT AM, Li R, O'Donnell MA, Black PC, et al
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review.
    Eur Urol. 2018;73:738-748.
    >> Share

    April 2018
  199. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    >> Share

  200. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    >> Share

  201. BOCHNER BH
    Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome.
    Eur Urol. 2018;73:558-559.
    >> Share

    March 2018
  202. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    >> Share

  203. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    >> Share

    February 2018
  204. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    >> Share

  205. NECCHI A, Anichini A, Sonpavde G
    Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.
    Eur Urol. 2018;73:153-155.
    >> Share

  206. WILSON SS, Crawford ED
    Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
    Eur Urol. 2018;73:233-235.
    >> Share

  207. SZABADOS B, van Dijk N, Tang YZ, van der Heijden MS, et al
    Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Eur Urol. 2018;73:149-152.
    >> Share

    January 2018
  208. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    >> Share

    December 2017
  209. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    >> Share

  210. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    >> Share

  211. OOSTERLINCK W, Decaestecker K
    Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project.
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31018.
    >> Share

  212. CUMBERBATCH MG, Catto JWF
    Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007.
    >> Share

    November 2017
  213. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    >> Share

  214. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    >> Share

  215. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    >> Share

  216. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    >> Share

    October 2017
  217. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    >> Share

    September 2017
  218. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    >> Share

  219. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    >> Share

    August 2017
  220. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    >> Share

    July 2017
  221. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    >> Share

    June 2017
  222. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    >> Share

  223. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    >> Share

  224. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    >> Share

  225. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    >> Share

  226. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    >> Share

  227. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    >> Share

  228. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    >> Share

  229. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    >> Share

  230. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    >> Share

    May 2017
  231. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    >> Share

  232. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    >> Share

  233. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    >> Share

  234. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    >> Share

  235. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    >> Share

  236. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    >> Share

    April 2017
  237. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    >> Share

  238. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    >> Share

  239. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    >> Share

  240. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    >> Share

  241. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    >> Share

  242. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    >> Share

    March 2017
  243. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    >> Share

  244. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    >> Share

  245. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    >> Share

  246. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    >> Share

    February 2017
  247. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    >> Share

  248. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    >> Share

  249. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    >> Share

    January 2017
  250. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    >> Share

  251. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    >> Share

  252. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    >> Share

  253. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    >> Share

    December 2016
  254. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    >> Share

    October 2016
  255. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    >> Share

  256. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    >> Share

    September 2016
  257. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    >> Share

  258. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    >> Share

    April 2016
  259. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    >> Share

  260. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    >> Share

    March 2016
  261. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    >> Share

    February 2016
  262. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    >> Share

  263. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    >> Share

  264. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016